Logiscreen

Fulgent Genetics Inc

$19.15
Market Cap 598.07M
ROE -6.7%
Gross Margin 30.2%
Debt/Equity 0.0
Current Ratio 5.3
Revenue QoQ -3.2%
EPS QoQ 1.2%
F-Score 3

About

Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a diagnostic business into a fully integrated precision medicine company. Source: Fulgent Genetics, Inc.

Exchange
NASDAQ
Sector
Healthcare
Industry
Diagnostics & Research

Sector context

Healthcare

Undervalued

Trading at a discount to sector peers

P/E
-8.25
vs median 31.50
P/B
0.58
vs median 2.17
ROE
-0.07
vs median 0.09

Lower quality - review fundamentals carefully

Small-cap company with higher volatility

Similar companies

Primary metric
Overlay metric
Loading chart data...
Fetching latest financial metrics